IDH2 and myeloproliferative neoplasm: The largest study that investigated the frequency of IDH1 and IDH2 mutations in Ph-negative MPN patients included 594 ET, 421 PV, 312 PMF, 95 post-PV/ET myelofibrosis and 51 blast-phase MPN patients [11].